49 minutes ago
A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.
1 hour ago
In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.
1 hour ago
The investigators seek to replicate the data in a future randomized control trial, and they hope to compare biofeedback to different therapies such as pulmonary rehabilitation.
2 hours ago
In part 5 of our 5-part discussion, experts discuss their perspective on appropriate guidance for screening age and the future of CRC advocacy.
2 hours ago
In part 4 of our 5-part discussion, experts discuss how to navigate conversations about risk factors and symptoms surrounding CRC.